Icatibant Xiromed, sol inj 30 mg/3ml , ser pré 3 ml
7680682630011
CH-68263
B06AC02
Reimbursement limitations:
FIRAZYR2
Traitement symptomatique des crises aiguës d’angio-œdème héréditaire (AOH) chez les adultes, les adolescents et les …
1 / 3
google
Details
- Product number
- -
- CPT
- -
- Packaging group
- -
- Unit
- -
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
30.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
9.9 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 806.15
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/07/2022
Authorization holder
Spirig HealthCare AG
4622 Egerkingen
Authorization information
- Swissmedic authorization number
- 68263
- Drug name
- Icatibant Spirig HC 30 mg, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- B06AC02
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 17/02/2022
- Authorization expiration date
- 16/02/2027
- IT number
- 02.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- ICATIBANT Xiromed sol inj 30 mg/3ml ser pré 3 ml
- Description (DE)
- ICATIBANT Xiromed Inj Lös 30 mg/3ml Fertspr 3 ml
- Narcotic (BTM)
- No